Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain

Background Gain and amplification of 1q21 (1q21+) are adverse chromosomal aberrations of multiple myeloma (MM) that lead to refractoriness to a variety of therapies. While it is known that daratumumab, an anti-cancer monoclonal antibody, cannot overcome the disadvantage of 1q21+in relapsed/refractor...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2024-07, Vol.120 (1), p.71-79
Main Authors: Iriuchishima, Hirono, Saito, Akio, Mihara, Masahiro, Terasaki, Yukie, Matsumoto, Akira, Isoda, Atsushi, Furukawa, Yusuke, Matsumoto, Morio
Format: Article
Language:English
Subjects:
Abnormalities
Amplification
Chromosome aberrations
Copy number
Cytogenetics
Effectiveness
Health care facilities
Hematology
Medicine
Medicine & Public Health
Monoclonal antibodies
Multiple myeloma
Oncology
Original Article
Patients
Survival
Thermal resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Gain and amplification of 1q21 (1q21+) are adverse chromosomal aberrations of multiple myeloma (MM) that lead to refractoriness to a variety of therapies. While it is known that daratumumab, an anti-cancer monoclonal antibody, cannot overcome the disadvantage of 1q21+in relapsed/refractory MM patients, its benefit in newly diagnosed MM (NDMM) patients with 1q21+has not been clarified. Patients We retrospectively evaluated 11 (55%) 1q21+patients (3 copies: 6, > 4 copies: 5) among 20 NDMM patients (median age, 74 years) who received daratumumab-containing regimens at Shibukawa Medical Center from October 2019 to October 2022. Results The overall response rate was 82% for patients with 1q21+and 78% for patients without 1q21+. Median progression-free survival (PFS) and median overall survival (OS) were not reached in either group. Neither 1q21 copy number nor co-existence of other high-risk cytogenetic abnormalities significantly affected PFS or OS. Conclusion Our preliminary data suggests that outcomes of daratumumab treatment in NDMM 1q21+patients might be non-inferior to those in non-1q21+patients.
ISSN:0925-5710
1865-3774
1865-3774
DOI:10.1007/s12185-024-03760-w